Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

about

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

Item

http://www.wikidata.org/entity/Q36535695

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@ast

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@en

type

Item

label

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@ast

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@en

prefLabel

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@ast

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@en

P1476

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

@en

P2093

Bicheng Yong

http://www.w3.org/2001/XMLSchema#string

Changye Zou

http://www.w3.org/2001/XMLSchema#string

Gang Huang

http://www.w3.org/2001/XMLSchema#string

Jin Wang

http://www.w3.org/2001/XMLSchema#string

Jingnan Shen

http://www.w3.org/2001/XMLSchema#string

Junqiang Yin

http://www.w3.org/2001/XMLSchema#string

Pingxian Tan

http://www.w3.org/2001/XMLSchema#string

Qianyong Wang

http://www.w3.org/2001/XMLSchema#string

Xianbiao Xie

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Primary bone osteosarcoma in the pediatric age: state of the art.

Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.

Using epidemiology and genomics to understand osteosarcoma etiology.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network.

Chemotherapy resistance in osteosarcoma: current challenges and future directions.

Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.

P2888

1477-7819-10-191

P304

191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1477-7819-10-191

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230869070

http://www.w3.org/2001/XMLSchema#string

P6179

1023379873

http://www.w3.org/2001/XMLSchema#string

P698

22985081

http://www.w3.org/2001/XMLSchema#string

P932

3545907

http://www.w3.org/2001/XMLSchema#string